C O N F E R E N C E P R O G R A Mwww.personalizedmedicineconference.org

Personalized Medicine: Impacting Healthcare

A Conference Hosted By

6th Annual Conference

November 17-18, 2010 Joseph B. Martin Conference Center at Harvard Medical School, Boston

HIGHLIGHTS FROM PAST CONFERENCES

3

November 17, 2010

Dear Colleague,

Welcome to the 2010 Personalized Medicine Conference. We and the other members ofthe Conference Organizing Committee, whose names you will see on the last page ofthis program, are pleased to offer this sixth annual gathering co-hosted by PartnersHealthCare, Harvard Medical School and Harvard Business School. We offer ourprofound thanks to the speakers, the panelists, the staff and our generous sponsors fortheir essential contributions.

This is a time of active and vigorous conversation at many different levels about thestate and future of healthcare. Invariably, those conversations recognize theextraordinary advances in knowledge and technological resources that have taken placein recent years. They also recognize the enticing opportunities for medical practice toimplement the principles of personalized medicine into routine practice. Many examplescan be cited in which those opportunities have been realized and are being applieddaily. At the same time, there are those who contend that personalized medicine is aconcept whose aspiration may far exceed its ultimate reality.

In the context of those differing opinions the annual Personalized Medicine Conferenceseeks to engage a diverse audience of national and international thought leaders indiscussions that will advance the understanding of and commitment to how the promiseof personalized medicine is being and may be further fulfilled. As you will see from thisyear’s program, we have sought to give attention both to accomplishments that havebeen made and to challenges to be overcome. We invite your active participation inthese discussions.

We are pleased to have our ongoing collaboration with the Personalized MedicineCoalition whose help brings added value in organizing and presenting the meeting.

Sincerely,

Raju Kucherlapati, Ph.DPaul C. Cabot Professor of Genetics andProfessor of Medicine, Harvard Medical School;Chair, Conference Organizing Committee

Scott T. Weiss, M.D., M.S.Scientific Director,Partners HealthCare Center forPersonalized Genetic Medicine;Professor of Medicine, Harvard Medical School

Thanks to Our SponsorsThis conference is organized by the Partners HealthCare Center for

Personalized Genetic Medicine and Harvard Business School in collaboration with the Personalized Medicine Coalition. It is made possible by the

generous support of our sponsors.

SIGNATURE

PLATINUM

GOLD

4

SILVER

BRONZE

CONTRIBUTING SPONSOR

5

6

Conference Program Wednesday, November 17, 2010

7:15 a.m.

8:15 a.m.

9:00 a.m.

9:30 a.m.

10:15 a.m.

11:20 a.m.

11:50 a.m.

1:05 p.m.

Registration & ContinentalBreakfast

Welcome

Opening Remarks

Keynote: A PharmaceuticalPerspective

Networking Break

Panel: The Cost and Valueof Personalized Medicinein the Era of Reform

Presentation ofPersonalized MedicineCoalition’s Sixth AnnualAward for Leadership inPersonalized Medicine

Luncheon

Debate: Patenting GeneTests: Judge RobertSweet’s Decision

Association for MolecularPathology, et al. v. UnitedStates Patent and TrademarkOffice, et al.

Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School

Scott Weiss, M.D., M.S.Scientific Director, Partners HealthCare Center for Personalized Genetic Medicine, Associate Director, Channing Laboratory, Professor of Medicine, Harvard Medical School

Elizabeth G. Nabel, M.D.President, Brigham and Women’s Hospital/Faulkner Hospital

Mikael Dolsten, M.D., Ph.D.President, Worldwide Research & Development, Pfizer

Introducer: Deborah Dunsire, M.D.President & CEO, Millennium: The Takeda Oncology Company

Moderator: Gregory J. Downing, D.O., Ph.D.Senior Advisor & Director, Personalized Health Care Initiative, U.S.Department of Health and Human Services

Introducer: Felix Frueh, Ph.D.VP, Personalized Medicine Research & Development, Medco Health Solutions

Jane Barlow, M.D., M.P.H., M.B.A.VP, Medical Strategy & Precision Health Solutions, Medco Health Solutions

Sharon Levine, M.D.Associate Executive Director, Permanente Medical Group

Arnold Milstein, M.D., M.P.H.Professor of Medicine, Stanford University School of Medicine, Medical Director, Pacific Business Group on Health

David Parker, Ph.D.VP, Boston Healthcare

William S. Dalton, Ph.D., M.D.President, CEO & Center Director, Moffitt Cancer Center

Presentation: Edward Abrahams, Ph.D.President, Personalized Medicine Coalition

Moderator: Carolyn JohnsonScience Writer, The Boston Globe

Introducer: Kathy GiustiFounder & CEO, Multiple Myeloma Research Foundation

Attorney for the Plaintiffs:Christopher A. Hansen, Esq., Staff Attorney, ACLU

Attorney for the Defendants: Jennifer Gordon, Ph.D., J.D., Partner, Baker Botts LLP

7

Conference Program Wednesday, November 17, 2010

1:50 p.m.

2:20 p.m.

3:25 p.m.

3:55 p.m.

5:00 p.m.

5:30-7:00 p.m.

Keynote: An InternationalPerspective

Panel: Implementation ofPersonalized Medicine inDiverse Sectors

Networking Break

Panel: MolecularDiagnostics: FromTechnologies toTreatments

Keynote: An InternationalPerspective

Reception at Elements Café

Charles Swanton, Ph.D.Head, Translational Cancer Therapeutics Laboratory, Cancer ResearchUK London Research Institute

Introducer: Nicholas Galakatos, Ph.D.,Managing Director, Clarus Ventures

Moderator: M. Kathleen Behrens Wilsey, Ph.D.Founder, KEW Group

Introducer: Heidi L. Rehm, Ph.D., FACMGLaboratory Director, Laboratory for Molecular Medicine, PartnersHealthCare Center for Personalized Genetic Medicine, AssistantProfessor of Pathology, Harvard Medical School

Mark S. Boguski, M.D., Ph.D.Associate Professor, Harvard Medical School, Beth Israel Deaconess Medical Center

Michael Bristow, M.D., Ph.D.Professor of Medicine, University of Colorado School of Medicine,Denver, Chief Executive Officer & President, ARCA biopharma

Bruce Johnson, M.D.Director, Lowe Center for Thoracic Oncology, Dana-Farber CancerInstitute, Professor of Medicine, Harvard Medical School

Clay Marsh, M.D.Senior Associate Vice President for Health Sciences Research, Vice Dean of Research, College of Medicine, Professor of InternalMedicine, Ohio State University

Moderator: Sue SiegelPartner, Mohr, Davidow Ventures

Introducer: Robert Tepper, M.D., Partner, Third Rock Ventures

William HagstromCEO, Crescendo Bioscience

K. Peter Hirth, Ph.D.Founder & CEO, Plexxikon

Ryan PhelanFounder & President, DNA Direct

Mark StevensonPresident & CEO, Life Technologies

Guilherme Suarez-Kurtz, M.D., Ph.D.Head of Pharmacology, Brazilian National Cancer Institute, Coordinator,Brazilian National Pharmacogenomics Network

Introducer: Lawrence J. Lesko, Ph.D., F.C.P.Director, Office of Clinical Pharmacology, Center for Drug Evaluationand Research, U.S. Food and Drug Administration

8

Conference Program Thursday, November 18, 2010

7:15 a.m.

8:15 a.m.

8:55 a.m.

10:00 a.m.

10:30 a.m.

10:55 a.m.

12:00 p.m.

Registration & Continental Breakfast

Perspectives from The U.S.Department of Health andHuman Services

Panel: Information TechnologySolutions

Keynote: A Perspective from anAcademic Medical Center

Networking Break

Radio Broadcast: On Point with Tom Ashbrook (off-site)

Bag Lunch

Anna Barker, Ph.D.Former Deputy Director, National Cancer Institute; DeputyDirector for Strategic Scientific Initiatives; Private Consultant

Lawrence J. Lesko, Ph.D., F.C.P.Director, Office of Clinical Pharmacology, Center for DrugEvaluation and Research, U.S. Food and Drug Administration

Introducer: Kristin Ciriello PothierVice President, Health Advances

Moderator: Neil de CrescenzoSenior Vice President and General Manager for HealthSciences, Oracle Corp.

Introducer: Richard A. MandahlVice President, Business Development, UNIConnect

David HickeyExecutive Vice President, Central Laboratory, Global Research &Development, Siemens Healthcare Diagnostics

Joseph M. Jasinski, Ph.D.IBM Distinguished Engineer, Global Industry Executive, SmarterHealthcare and Life Sciences, IBM Research

Emad Rizk, M.D.President, McKesson Health Solutions

William Chin, M.D.Executive Dean for Research, Harvard Medical School

Introducer: Per G. H. LofbergExecutive Vice President, CVS Caremark, President, CaremarkPharmacy Services

Facilitator: Edward Abrahams, Ph.D.President, Personalized Medicine Coalition

Host: Tom AshbrookHost & Managing Editor, On Point, WBUR, National PublicRadio

Guest: Margaret A. Hamburg, M.D.Commissioner of Food and Drugs, U.S. Food and DrugAdministration (invited)

9

Conference Program Thursday, November 18, 2010

12:30 p.m.

1:00 p.m.

1:30 p.m.

2:15 p.m.

3:45 p.m.

Keynote: FDA Perspective onPersonalized Medicine

National Legislative Efforts

Briefings: Investments inPersonalized Medicine

Interactive Case Studies onBusiness Strategies forPersonalized Medicine

Case 1: Plavix: Drugs in the Age of Personalized Medicine

Case 2: Genomic Databases

Closing Remarks

Margaret A. Hamburg, M.D.Commissioner of Food and Drugs, U.S. Food and DrugAdministration (invited)

Sheila WalcoffPartner, McDermott Will & Emery

Risa Stack, Ph.D.Partner, Kleiner Perkins Caufield & Byers

Introducer: Gerald McDougallPartner, PricewaterhouseCoopers

Christopher-Paul Milne, D.V.M., M.P.H., J.D.Associate Director, Tufts Center for the Study of DrugDevelopment, Tufts University

Sara RadcliffeExecutive Vice President for Health, Biotechnology IndustryOrganization (BIO)

Introducer: Jeffrey Elton, Ph.D.Chief Executive Officer, KEW Group

Moderators:Richard Hamermesh, D.B.A.MBA Class of 1961 Professor of Management Practice, Harvard Business School

Mara AspinallPresident & Chief Executive Officer, On-Q-ity

Introducer: Gwill YorkFounder and Managing Director, Lighthouse Capital Partners

Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics, Professor of Medicine,Harvard Medical School

10

Edward Abrahams, Ph.D.Edward Abrahams is president of thePersonalized Medicine Coalition (PMC).Representing a broad spectrum of aca-demic, industrial, patient, provider andpayer communities, PMC seeks toadvance the understanding and adoptionof personalized medicine concepts and

products for the benefit of patients. It has grown from itsoriginal 18 founding members in November 2004 to over175 today.Previously Dr. Abrahams was Executive Director of the

Pennsylvania Biotechnology Association, where he spear-headed the successful effort that led to the Commonwealthof Pennsylvania’s investment of $200 million to commer-cialize biotechnology in the state. Earlier he had beenAssistant Vice President for Federal Relations at theUniversity of Pennsylvania and held a senior administrativeposition at Brown University.Dr. Abrahams worked for seven years for the U.S.

Congress, including as a legislative assistant to SenatorLloyd Bentsen, an economist for the Joint EconomicCommittee under the chairmanship of Representative LeeHamilton, and as a AAAS Congressional Fellow for theHouse Committee on the Interior.The author of numerous essays, Dr. Abrahams serves as

senior editor of Personalized Medicine and has also taughthistory and public policy at Brown University and theUniversity of Pennsylvania.

Mara AspinallMara Aspinall is president and chiefexecutive officer of On-Q-ity, an innova-tive personalized medicine oncology biol-ogy company focused on informing andtransforming cancer life cycle manage-ment through diagnostics. The companyis developing diagnostics to identify the

unique characteristics of an individual's cancer, predictingthe response to therapy and monitoring the efficacy oftreatment in multiple cancer types. On-Q-ity leverages twocore technologies: Microfluidic chip technology to capture,enumerate, and characterize circulating tumor cells (CTC)from patient blood and DNA repair pathway biomarkers topredict treatment response.Mara was previously president of Genzyme Genetics, a

leading provider of testing in the oncology and reproduc-tive markets. Under Mara's leadership, Genzyme Geneticsset the standard for quality genetics testing in the industry,

while profitably growing at an unprecedented pace. Shetransformed the business, expanding its scope and reach tobecome one of the nation’s largest diagnostic laboratories.Before that, Mara served as president of GenzymePharmaceuticals. Mara is a Board member of the Personalized Medicine

Coalition and a founding director of EPEMED, the EuropeanPersonalized Medicine organization. Mara holds anappointment as lecturer in health care policy at HarvardMedical School and has taught a seminar on The Businessof Drugs and Diagnostics. She has been an active memberof the Federal Secretary of Health and Human Services’Advisory Committee on Genetics, Health and Society. Maraco-authored, “Realizing the Promise of PersonalizedMedicine” in the Harvard Business Review and, mostrecently, was named one of the 2010 “100 Most InspiringPeople in Life Sciences” by PharmaVOICE Magazine.Mara started her business career at Bain & Company, an

international strategic consulting firm. Her MBA is fromHarvard Business School and her BA from Tufts University.

Anna Barker, Ph.D.Anna Barker served as the DeputyDirector of the National Cancer Institute(NCI) and as the Deputy Director forStrategic Scientific Initiatives for the pasteight years – retiring at the end ofAugust, 2010. In this role she developedand implemented multi/trans-disciplinary

programs in strategic areas of cancer research andadvanced technologies including: the NanotechnologyAlliance for Cancer; The Cancer Genome Atlas (TCGA) – incollaboration with the National Human Genome ResearchInstitute; and the Clinical Proteomics Technologies Initiativefor Cancer. Recently she led the development of a new ini-tiative to develop a network of trans-disciplinary centersfocused on the elucidation of the “physics” of cancer at allscales through the establishment of Physical Sciences-Oncology Centers (PS-OCs). All of these programs empha-size innovation, trans-disciplinary teams and convergenceof scientific disciplines to enable progress against cancer.They also stress the synergy of large scale and individualinitiated research, precompetitive research and public data-bases and translation of discoveries into new targetedinterventions to detect prevent and treat cancer more effec-tivelyDr. Barker has also led and collaborated on NCI’s effort to

develop contemporary resources for cancer research in theareas of biospecimens and bioinformatics (the Cancer

Conference Speakers

11

continued

Human Biobank (caHUB) and the Cancer BioinformaticsGrid (caBIG, respectively) to support molecularly based per-sonalized medicine. She served as the founding co-chair ofthe NCI-FDA Interagency Task Force; founding co-chair ofthe Cancer Steering Committee of the FNIH BiomarkerConsortium; and oversaw the NCI’s international cancerresearch programs, including pilot programs in LatinAmerica and China. Dr. Barker has a long history inresearch and the leadership and management of researchand development in the academic, non-profit and privatesectors. She served as a senior scientist and subsequentlyas a senior executive at Battelle Memorial Institute for 18years; and co-founded and served as the CEO of a publicbiotechnology drug development company. She hasreceived a number of awards for her work in support ofcancer research, cancer patients, professional and advocacyorganizations and the ongoing national effort to preventand cure cancer. Most recently she received the 2009 AACRMargaret Foti Award for Leadership and ExtraordinaryAchievements in Cancer Research, AACR 100th AnniversaryMeeting; and In 2009 Dr. Barker was named to the list of“The 100 People Changing America” by Rolling StoneMagazine.Her research interests include experimental therapeutics,

tumor immunology, and free-radical biochemistry in canceretiology and treatment. Dr. Barker completed her M.A. andPh.D. at the Ohio State University, where she trained inimmunology and microbiology.

Jane Barlow, M.D., M.P.H, M.B.A.Jane Barlow serves as Vice President,Medical Strategy and Precision HealthSolutions for Medco Health Solutions,Inc. Dr. Barlow is responsible for strate-gy, design and delivery of Medco’s per-sonalized medicine products and servicestargeted at improving therapy manage-

ment and treatment outcomes through focused genetic andmolecular testing. As medical director for Medco’s employ-er clients, she engages in strategic discussions leveragingMedco’s clinical expertise to aid clients with planning, pro-gram design and outcomes measures across the full spec-trum of health benefits. She is also provides comprehensiveleadership and oversight of Medco's accreditation activitiesand annual Drug Trend Report.Dr. Barlow’s prior experience includes expertise in

employer benefits, employee well-being, and occupationaland environmental health and safety. Her diverse back-ground includes positions with the U.S. military, federal gov-

ernment, industry, private practice and consulting. Dr. Barlow attended medical school at Creighton

University and completed her residency training in occupa-tional medicine at Johns Hopkins University. She holdsmasters’ degrees in business administration and publichealth and is a Certified Physician Executive. Dr. Barlow isboard-certified in occupational medicine and holds the rankof fellow in both the American College of Occupational andEnvironmental Medicine and the American College ofPreventive Medicine.

Mark Boguski, M.D., Ph.D.Mark Boguski is a well-known leader in informatics andgenomics research. He has written and lectured extensivelyon bioinformatics and genomics, and developed the firstpublicly available database system for expression arraydata. Dr. Boguski leads bioinformatics specialists and exper-imental biologists in developing the interface betweencomputational biology and functional genomics to gainnew insights into systems biology. An original member ofthe U.S. National Center for Biotechnology Information(NCBI), Dr. Boguski has been involved with the develop-ment of a number of high-impact, enabling informationresources. These include: dbEST, a critical resource for genediscovery and in silico SNP mining; applications of UniGenefor creation of the first large-scale maps of the humangenome and the design of gene chips from expression pro-filing; and ArrayDB for management and analysis of expres-sion data. He has also made significant contributions tocomparative genomics and pharmacogenomics.Dr. Boguski is the author or co-author of over 100 articlesand is the recipient of the Regents' Award from theNational Library of Medicine and the NIH Director's Award.He is an organizer of the Cold Spring Harbor Symposium onGenome Sequencing and Biology and has served on grantreview and advisory panels for a number of governmentand private funding agencies and as a consultant to indus-try. He is an adjunct Professor in the Department ofMolecular Biology and Genetics at the Johns HopkinsUniversity School of Medicine, a former Editor of GenomeResearch and serves on the Board of Reviewing Editors forScience magazine. Dr. Boguski is a member of the ScientificAdvisory Board of the Merck Genome Research Institute, amember of the Genetics Advisory Group for the WellcomeTrust and an advisor to the Howard Hughes MedicalInstitute. He received his M.D. and Ph.D. degrees from theMedical Scientist Training Program at the WashingtonUniversity School of Medicine in St. Louis and pursued spe-cialty training in pathology.

12

Conference Speakers continued

Michael Bristow, M.D., Ph.D.,Michael R. Bristow is currently Professorof Medicine (Cardiology) and Co‐Directorof the University of ColoradoCardiovascular Institute at the Universityof Colorado, School of Medicine inDenver. He headed the CardiologyDivision there from 1991 to 2004.

Dr. Bristow received his MD in 1970 from the Universityof Illinois in Chicago, where he also earned a PhD in phar-macology the following year. After completing an NIH post-doctoral fellowship in pharmacology at the University ofIllinois, he received his medical training at StanfordUniversity, including an internship in internal medicine, aresearch fellowship in medicine/oncology, and a residencyin medicine. He remained at Stanford to complete a fellow-ship in cardiology, where he joined the Cardiology faculty in1979. He moved to the University of Utah in 1984, wherehe co‐founded the first multi‐hospital heart transplant pro-gram in the U.S. Dr. Bristow is board certified in internalmedicine and in the subspecialty of cardiovascular diseases.Dr. Bristow has authored more than 350 peer‐reviewed

papers and book chapters on heart failure and other cardio-vascular diseases. He was instrumental in elucidating keymolecular mechanisms underlying heart failure and the useof β‐blockers for its treatment, and in developing the firstpharmacogenetically targeted cardiovascular drug (bucin-dolol, Gencaro™), currently under consideration for FDAapproval. He was the lead investigator for the Comparisonof Medical Therapy, Pacing, and Defibrillation in ChronicHeart Failure (COMPANION) trial, and he was involved inthe leadership of many other heart failure trials, includingthe Beta‐Blocker Evaluation of Survival Trial (BEST) and theU.S. Carvedilol Trials. He has received many academic andindustry honors, including the Therapeutic Frontiers Award,presented by the American College of Clinical Pharmacy, fordevelopment of β‐blockade as a treatment for chronicheart failure, and in 2008 the Pharmaceutical Research andManufacturers of America Clinical Trial Exceptional ServiceAward for the development of carvedilol for heart failure. In2008 he was given the Lifetime Achievement Award by theHeart Failure Society of America. In 1999 he was ranked byScience Watch as first among heart failure investigators inimpact of cardiovascular publications between 1993 and1997, and he is an original member (2002) of the Instituteof Scientific Information's Highly Cited Researchers.He is a fellow of the American College of Cardiology, a

founding member of the Heart Failure Society of America,

and a member of many other professional societies. He cur-rently serves on the editorial boards of The Journal of theAmerican College of Cardiology, Congestive Heart Failure,The International Journal of Cardiology and Clinical andTranslational Science among other journals.Dr. Bristow is the chairman and chief science and medical

officer of ARCA Biopharma, a company he founded in 2002with the mission of developing genetically targeted thera-pies for heart failure and other cardiovascular diseases. In2007, he co‐founded Miragen Therapeutics, Inc., a companydedicated to utilizing the biologic properties of microRNAin developing therapies for cardiovascular diseases. He wasalso the principal founder and former chief science andmedical officer of Myogen, Inc., a biopharmaceutical com-pany that was acquired by Gilead Sciences, Inc., in 2006.These companies, all founded on university‐licensed intel-lectual property generated by him and his collaborators,have been responsible for creating hundreds of jobs inColorado and in the case of Myogen being named businessof the year in its home office location (Westminster, CO).Companies founded by Dr. Bristow have been responsiblefor developing one FDA and EMEA approved drug(Ambrisentan, Letairis™ for pulmonary arterial hyperten-sion), one submitted NDA (bucindolol) and one cardiovas-cular drug in late‐stage development (darusentan, forresistant hypertension), and have returned over 2B USD toinvestors. In 2008, he was given the Lifetime AchievementAward by the Heart Failure Society of America, and alsonamed "Scientist of the Year" by the Colorado Chapter ofthe ARCS.

William W. Chin, M.D.William Chin is the Executive Dean forResearch at Harvard Medical School(HMS). In this role, Dr. Chin spearheadsefforts to design and implement thevision for research at HMS, with specialemphasis on interdisciplinary and trans-lational research that crosses departmen-

tal and institutional boundaries. Chin is a Harvard-trainedendocrinologist and longstanding faculty member. He wasProfessor of Medicine, HMS; Chief, Division of Genetics andSenior Physician, Brigham & Women’s Hospital; andInvestigator, Howard Hughes Medical Institute. His impres-sive career is exemplified in part by his extensive bibliogra-phy of nearly 300 papers, chapters and books, most ofwhich were generated during his 25 years at HMS. As apioneering molecular endocrinologist at HMS, Dr. Chin

13

embraced the early use of emerging DNA technology tomake important discoveries regarding the structure, func-tion and regulation of hormone genes. His investigationsoften demonstrated a translational research theme, con-necting basic laboratory discoveries to their physiologic rel-evance in animal models and humans. He has been hon-ored with numerous awards for research, mentorship andleadership. Prior to HMS, Dr. Chin was at Eli Lilly andCompany, where he had worked for the last decade, mostrecently as senior vice president for Discovery Research andClinical Investigation.

William Dalton, Ph.D., M.D.William (Bill) S. Dalton is President, ChiefExecutive Officer and Center Director ofMoffitt Cancer Center and ResearchInstitute, an NCI-DesignatedComprehensive Cancer Center, andserves as Board Chairman of M2Gen, anational biotechnology subsidiary of

Moffitt Cancer Center. A nationally renowned cancerresearcher, physician and health policy expert, Dr. Daltonhas dedicated his career to the study and development ofthe most effective approaches to cancer research and care. Dr. Dalton currently serves as the President-Elect of the

Association of American Cancer Institutes and is Chair ofthe Science Policy & Legislative Affairs Committee of theAmerican Association for Cancer Research. Dr. Daltonserved on the National Cancer Institute Board of ScientificAdvisors as well as multiple scientific advisory boards atcancer centers and research foundations across the U.S.In addition to his basic and translational research inter-

ests in molecular mechanisms of drug resistance and newdrug discovery, in which he has been funded continuouslyby the NIH/NCI for over 25 years and holds several patents,Dr. Dalton is also interested in the development of person-alized cancer care and patient-centered outcomes research.Moffitt’s Total Cancer CareTM is an approach to enhancingaccess to evidence-based, personalized cancer treatmentsand information/decision tools for patients and clinicians.Total Cancer Care is one of the largest cancer tumor bio-repositories and data warehouses in the U.S. dedicated foruse in development of personalized medicine. Dr. Dalton has authored or co-authored numerous articles

in journals such as Cancer Research, Blood, Immunity, andthe Journal of Biochemistry. He serves, or has served, onthe editorial boards of Clinical Cancer Research, MolecularCancer Therapeutics, Archives of Internal Medicine,

Leukemia, Cancer Research, and Investigational New Drugs. Dr. Dalton received his Ph.D. in toxicology and medical

life sciences and his M.D. degree from Indiana University.He completed his internship in Internal Medicine at IndianaUniversity, his residency in Medicine at the University ofArizona in Tucson and his fellowships in Oncology andClinical Pharmacology at the University of Arizona. He isboard certified in Internal Medicine and Medical Oncologyand is an expert in Multiple Myeloma. Prior to acceptingthe position as CEO/Center Director at Moffitt, Dr. Daltonwas the Dean of the College of Medicine at the Universityof Arizona.

Neil de CrescenzoNeil de Crescenzo is Senior Vice President and GeneralManager for Health Sciences at Oracle Corporation. He isresponsible for managing Oracle’s solution groups, strategicplanning, product development, sales, service and supportfor the industry solutions sold into the healthcare and lifesciences markets worldwide. He brings over 20 years ofoperational and IT leadership across healthcare and life sci-ences to his work with customers and partners worldwide.Oracle is the world's leading supplier of enterprise soft-ware, with over $25B in revenues and over 100,000employees.Prior to joining Oracle, Mr. de Crescenzo held a number

of leadership positions at IBM Corporation for a decade,working with healthcare and life sciences clients world-wide. Prior to entering the information technology industry,he held leadership positions in healthcare operations atmedical centers and a major health insurer.Mr. de Crescenzo has been a keynote speaker at numer-

ous industry conferences worldwide and is quoted fre-quently on industry issues. In 2005, he was named one ofthe Top 25 Most Influential Consultants by ConsultingMagazine. Mr. de Crescenzo has a B.A. in Political Sciencefrom Yale University and an MBA in High Technology fromNortheastern University.

Mikael Dolsten, M.D., Ph.D.Mikael Dolsten was appointed Presidentof Worldwide Research & Development(WRD) in May, 2010. In this role, he hasresponsibility for all research at Pfizer, aswell as development of all compoundsthrough proof of concept (POC). A physi-cian with more than 20 years experience

in the pharmaceutical industry, Mikael oversees thousands

continued

14

Conference Speakers continued

of world-class scientists and researchers progressing a port-folio of high-impact medicines and vaccines to transformpatients’ lives. Pfizer scientists across WRD apply industry-leading scien-

tific and technology expertise across a range of small mole-cule and biologic platforms and modalities. In a global net-work of research laboratories and clinical study sites, PfizerR&D professionals and business unit colleagues focus ontranslating deep science into safe and effective drugs toprevent, treat and cure disease.Mikael oversees all Pfizer research units and biotech

units in PharmaTherapeutics and BioTherapeutics:Antibacterials; Allergy & Respiratory; Cardiovascular,Metabolic & Endocrine Diseases; Neuroscience; Oncology;Pain; Regenerative Medicine; Indications Discovery;Inflammation & Immunology; Tissue Repair; BioCorrection;Orphan & Genetic Diseases; New Opportunities; TherapeuticInnovation Laboratories; Vaccine R&D; CovX; Rinat;Oligonucleotide Therapeutics; and the Center for IntegrativeBiology & Biotherapeutics.WRD also includes these global science-based groups:

Medicinal Chemistry; Drug Safety R&D; PharmaceuticalSciences; Pharmacokinetics, Dynamics & Metabolism;Comparative Medicine; Clinical Research; Clinical Programs;Development Operations; Development & StrategicOperations; External R&D Innovation; Research Centers ofEmphasis; and Asia R&D. Previously, Mikael was Presidentof BioTherapeutics R&D, responsible for driving Pfizer lead-ership, expertise, and innovation in biologic medicines andvaccines. Prior to joining Pfizer in 2009, Mikael was SeniorVice President, Wyeth Inc. and President of Wyeth Researchwhere he led scientists across the U.S., Europe and Asia inthe research and development of small molecules, vaccinesand protein-based medicines in Inflammation, WomenHealth’s, Neuroscience, Oncology, Infectious diseases (vac-cines, antibiotics), Hemophilia, GI and Musculoskeletal dis-eases. Before joining Wyeth, Mikael served as Executive Vice

President within Pharmaceutical Research &Development/Medicine at Boehringer Ingelheim. He ledpharmaceutical research in the U.S., Canada, Germany, Italy,Austria and Japan – with programs in respiratory, inflam-mation/immunology, oncology, virology, cardiovascular,metabolism and CNS. He was a member of the BI corpo-rate management team responsible for all worldwide devel-opment projects and licensing opportunities. Mikael’s earli-er career included research leader positions withAstraZeneca, Pharmacia and Upjohn.Mikael earned his Ph.D. in tumor immunology and M.D.

from the University of Lund in Sweden. He also studiedvirology and cell biology at the Weizmann Institute in Israeland has been appointed as Adjunct Professor inImmunology at the Medical Faculty in Lund. In July 2010, Mikael was elected a fellow of the New YorkAcademy of Medicine. He is an appointed Governor of theNew York Academy of Sciences. A member of the Scienceand Regulatory Executive Committee of The PharmaceuticalResearch and Manufacturers of America (PhRMA), Mikaelalso serves on the PhRMA Foundation Board of Directors. Mikael has published several patents and about 150 arti-

cles in international journals with particular contributions inareas such as molecular cell biology, immunology andoncology.

Gregory J. Downing, D.O., Ph.D.Gregory Downing was appointed inMarch 2006 as Program Director for theDepartment of Health and HumanServices (HHS) initiative on PersonalizedHealth Care. In this role, he coordinatestrans-HHS agency programs for theanalysis, planning and implementation of

policies and systems to facilitate integration of technologiesto advance the quality of health care. Prior to coming to HHS, Dr. Downing served at the

National Institutes of Health since 1993 in research, policy,and program management roles. Dr. Downing earned hismedical degree from Michigan State University and hisPh.D. in pharmacology from the University of Kansas. Hecompleted his residency in pediatrics and fellowship inneonatology before joining the faculty of the University ofMissouri-Kansas City in the Department of Neonatology atThe Children’s Mercy Hospital. Dr. Downing is certified bythe American Board of Pediatrics in pediatrics and neona-tology — perinatal medicine.

Jennifer Gordon, Ph.D., J.D.Jennifer Gordon is a partner in the NewYork office of Baker Botts, LLP and headof the firm’s Life Sciences IntellectualProperty practice. She has extensiveexperience in the area of biotechnologyand pharmaceutical patent law. Herpresent practice is largely in the area of

patent litigation with ongoing involvement in various pros-ecution matters (including reexaminations) before theUnited States Patent and Trademark Office), client counsel-ing (including validity, infringement, patentability and free-

15

dom-to-operate opinions), and appeals before the Court ofAppeals for the Federal Circuit. Her patent cases havespanned various aspects of biotechnology such as nucleicacid amplification technologies, recombinant DNA technolo-gies, enzymology, virology, medical diagnostics and pharma-ceuticals.Dr. Gordon is a graduate of the Massachusetts Institute

of Technology, where she was awarded an S.B. degree inLife Sciences in 1975 and a Ph.D. degree in BiochemicalEngineering in 1981. She attended Fordham UniversitySchool of Law where she graduated with a J.D. degree, cumlaude, in 1985. She is a native, and current resident, ofBrooklyn, New York.

William HagstromWilliam Hagstrom has served as theChief Executive Officer of CrescendoBioscience since early 2007. Mr.Hagstrom has over 25 years of experi-ence in the healthcare industry includingdiagnostics, devices and therapeutics.Prior to Crescendo Bioscience, William

was President of Alpha BioPartners a strategic consultingfirm concentrated on assessing promising technologies andlaunching new life sciences companies. Previously, Mr.Hagstrom served as President and Chief Executive Officer ofUroCor, a specialty diagnostics company focused on urolog-ical cancers and complex diseases. In this role, he built theCompany from start-up through market launch, productexpansion and penetration of over 35% of the U.S. Urologymarket. Urocor’s growth placed the Company on the Inc500 list of fastest growing private companies in 1992,1993, 1994 and 1995. In 1996 UroCor successfully com-pleted its Initial Public Offering. Prior to joining UroCor, hespent 10 years with large multi-national healthcare compa-nies including Baxter Travenol, American Hospital Supplyand Becton Dickinson. Within these companies, Mr.Hagstrom held a broad range of positions in general man-agement, senior marketing and sales along with productplanning and business development.

Margaret A. Hamburg, M.D.Margaret A. Hamburg was confirmed on May 18, 2009 by aunanimous Senate voice vote to become the 21stCommissioner of Food and Drugs. The second woman to benominated for that position, Dr. Hamburg is exceptionallyqualified for her new job by her training and experience asan M.D., scientist and public health executive.

Dr. Hamburg graduated from Harvard Medical School,and completed her residency in internal medicine at what isnow New York Presbyterian Hospital-Weill Cornell MedicalCenter, one of the top-ten hospitals in the nation. She con-ducted research on neuroscience at Rockefeller University inNew York, studied neuropharmacology at the NationalInstitute of Mental Health on the National Institutes ofHealth campus in Bethesda, Md., and later focused on AIDSresearch as Assistant Director of the National Institute ofAllergy and Infectious Diseases.In 1990, Dr. Hamburg joined the New York City

Department of Health and Mental Hygiene as DeputyHealth Commissioner, and within a year was promoted toCommissioner, a position she held until 1997. During hertenure she was widely praised for her initiatives, decisiveleadership, and significant public health measures she car-ried out despite severe budget constraints and while hold-ing academic positions at Columbia University School ofPublic Health and Cornell University Medical College.Dr. Hamburg's accomplishments as New York's top public

health official included improved services for women andchildren, needle-exchange programs to reduce the spreadof HIV (the AIDS virus), and the initiation the first publichealth bio-terrorism defense program in the nation. Hermost celebrated achievement, however, was curbing thespread of tuberculosis. In the 1990s, TB resurged as a majorpublic health threat, largely because many patients did notcomplete the full course of the treatment and the diseasebecame resistant to standard drugs. Dr. Hamburg confront-ed the problem by sending health care workers to patients’homes and taking other steps to make sure they completedthe drug regimen. Thanks to this program, in a five-yearspan, the TB rate in New York City fell by 46% overall, and86% for the most drug-resistant strains. Dr. Hamburg'sinnovative approach has become a model for health depart-ments world-wide.In 1994, Dr. Hamburg was elected to the membership in

the Institute of Medicine, one of the youngest persons to beso honored. Three years later, at the request of PresidentClinton, she accepted the position of Assistant Secretary forPolicy and Evaluation in the U.S. Department of Health andHuman Services (HHS).In 2001, Dr. Hamburg became Vice President for

Biological Programs at the Nuclear Threat Initiative, a foun-dation dedicated to reducing the threat to public safetyfrom nuclear, chemical, and biological weapons. In thatposition, she has advocated broad reforms in public healthinfrastructure and policy, from local health departments to

continued

16

Conference Speakers continued

the national agency, in order to meet the dangers of mod-ern bioterrorism as well as the threats of naturally occur-ring infectious diseases such as pandemic flu. Since 2005,Dr. Hamburg has served as the Initiative's Senior Scientist.President Barack Obama nominated her for the FDACommissioner on March 25, 2009.Upon Dr. Hamburg's confirmation by the U.S. Senate, HHS

Secretary Kathleen Sebelius has praised her as "an inspiringpublic health leader with broad experience in infectious dis-ease, bioterrorism, and health policy,” and added that"Personally, I have been impressed by the calm and confi-dence Dr. Hamburg has shown in the face of a wide varietyof challenges."

Richard Hamermesh, D.B.A.Richard Hamermesh is the MBA Class of1961 Professor of Management Practiceat the Harvard Business School where heteaches in the MBA Program and is theFaculty Chair of the HBS HealthcareInitiative. Richard created and teachesthe second-year MBA elective,

Entrepreneurship and Venture Capital in Healthcare.Previously, he was the Course Head for the required firstyear course entitled The Entrepreneurial Manager. In addi-tion Richard participates in several HBS Executive Educationprograms.From 1987 to 2001, Richard was a co-founder and a

Managing Partner of The Center for Executive Development,an executive education and development consulting firm.Prior to this, from 1976 to 1987, he was a member of thefaculty of the Harvard Business School.Richard is also an active investor and entrepreneur, hav-

ing participated as a principal, director, and investor in thefounding and early stages of over 20 organizations. Thesehave included start-ups, leveraged buy-outs, industry roll-ups, and non-profit foundations. He was the founding presi-dent of the Newton (MA) Schools Foundation and servedon the editorial board of the Harvard Business Review. He iscurrently on the Boards of one public and two private cor-porations, as well as two non-profit Boards. From 1991 to1996, he was the founding Chairman of Synthes Spine, Inc.Richard is the author or co-author of five books, includ-

ing New Business Ventures and the Entrepreneur. His best-known book,Fad-Free Management, was published in 1996.He has published numerous articles and more than 100case studies. His most recent article, "Realizing thePotential of Personalized Medicine," appeared in the

Harvard Business Review (October 2007). Richard receivedhis AB from the University of California, and his MBA andDBA from HBS. He is married, has two children, and hishobbies include tennis, skiing, and yoga.

Christopher Hansen, Esq.Chris Hansen joined the ACLU in 1973.He spent 10 years at the NYCLU special-izing in complex litigation seeking reformof the mental retardation and mentalhealth systems. He then spent 10 yearsas the Associate Director of theChildren’s Rights Project of the ACLU

specializing in complex litigation seeking reform of childwelfare systems and in school desegregation. Since themid-1990’s, Mr. Hansen has been a staff attorney at theACLU and worked on a wide variety of cases. He led theACLU’s decades-long, successful battle to ensure thatspeech on the Internet receive the highest First Amendmentprotection. Most recently, he led the ACLU’s effort to invali-date patents granted on human genes. Mr. Hansen hasargued cases in the US Supreme Court, and many of thefederal courts of appeals, federal district courts, and statetrial and appellate courts.

David HickeyDave Hickey was appointed ExecutiveVice President, Central Laboratory, GlobalResearch & Development of SiemensHealthcare Diagnostics in February 2009.Dave also served as Senior VicePresident, Central Laboratory, Strategyand Business Development and prior to

that he served as Senior Vice President Strategic Marketingand Planning since January, 2007, and prior to that VicePresident, Immunology and Molecular for BayerDiagnostics. Dave is now responsible for the central labora-tory business, global research & development, programmanagement and medical, clinical and statistical affairsincluding plans for the integration of the in vivo and invitro diagnostic solutions. Mr. Hickey joined BayerDiagnostics in 1992 as Product Manager, Clinical Chemistry.In 1996, he was appointed to Marketing Manager,Immunoassay and Clinical Chemistry.Mr. Hickey became Head of Sales and Marketing for

Bayer’s Near Patient Testing and Diabetes Care Divisions inthe U.K. in 2000. When he was promoted to Vice President,Immunology and Molecular for Bayer Diagnostics in 2004,

17

he assumed responsibility for the global strategic marketingof the immunology and molecular assays and instruments,including new product launch operations. Prior to joining Bayer Diagnostics, Mr. Hickey served as a

field product specialist for laboratory analyzers forAmerican Monitor, Inc. He also provided sales and territorymanagement for British Drug Houses (BDH), and was a clin-ical biochemist at a district general hospital in the UK,working in Chemical Pathology.Mr. Hickey holds a B.S. in Clinical Biochemistry from

University of Manchester.

K. Peter Hirth, Ph.D K. Peter Hirth co-founded Plexxikon inDecember 2000, and has 25 years ofbiotechnology and pharmaceutical dis-covery and development experience.Previously, he was president of Sugen,Inc. until the sale of the company toPharmacia Corporation in 1999. At

Sugen, he helped build the company from its inception andadvanced several kinase inhibitors through clinical trials forthe treatment of oncology. This includes the drug Sutent,now owned by Pfizer through its acquisition of Pharmacia.Prior to Sugen, Dr. Hirth was a vice president in researchwith Boehringer Mannheim where, among other responsi-bilities, he successfully led the company's erythropoietinprogram. Previously, he also was a research scientist withthe Max Planck Institute, following the completion of hispost doctoral work at the University of California, SanDiego. Dr. Hirth received his Ph.D. in molecular geneticsfrom Heidelberg University, Germany.

Joseph Jasinski, Ph.D.Joseph M. Jasinski is an IBMDistinguished Engineer and the GlobalIndustry Executive for Smarter Healthcareand Life Sciences at IBM Research. Inthis role he is responsible for developingstrategies and coordinating researchefforts across IBM's Research Division in

areas ranging from the use of information technology inpayer/provider healthcare to computational studies inmolecular biology.Dr. Jasinski is a Fellow of the American Physical Society

and the American Association for the Advancement ofScience. He has authored or co-authored over 50 scientificpapers and holds two patents.

Bruce Johnson, M.D.Bruce E. Johnson received his MD fromthe University of Minnesota in 1979 andhis postgraduate training at theUniversity of Chicago and the NationalCancer Institute. After serving at NCI,where he most recently headed the LungCancer Biology Section, he joined DFCI in

1999. He currently directs the Dana-Farber/PartnersCancerCare Thoracic Oncology Program, a cooperativeeffort that includes DFCI, Brigham and Women's Hospital,and Massachusetts General Hospital.

Carolyn JohnsonCarolyn Johnson joined the Boston Globe’s Health andScience department as its science writer in July 2008.Before that she covered telecom and tech culture for thebusiness section. Carolyn was a physics and English majorat Amherst and she has a master's degree in sciencewriting from MIT.

Raju Kucherlapati, Ph.D. Raju Kucherlapati is the Paul C. CabotProfessor in the Harvard Medical SchoolDepartment of Genetics. He is also a pro-fessor in the Department of Medicine atBrigham and Women's Hospital. Dr.Kucherlapati was the first ScientificDirector of the Harvard Medical School-

Partners Healthcare Center for Genetics and Genomics. Hisresearch focuses on gene mapping, gene modification, andcloning disease genes. During 1989-2001, Dr. Kucherlapatiwas the Lola and Saul Kramer Professor of MolecularGenetics and Chairman of the Department of MolecularGenetics at the Albert Einstein College of Medicine in NewYork. He was previously a professor in the Department ofGenetics at the University of Illinois, College of Medicine.He began his research as an assistant professor in theDepartment of Biochemical Sciences at Princeton University. He has chaired numerous NIH committees and served on

the National Advisory Council for Human Genome Researchand the NCI Mouse Models for Human Cancer Consortium.He is also a member of the Cancer Genome Atlas project ofthe National Institutes of Health. He is a member of theInstitute of Medicine of the National Academy of Sciencesand a fellow of the American Association for theAdvancement of Science. He is a member of PresidentialCommission for the Study of Bioethical Issues.

continued

18

Conference Speakers continued

Dr. Kucherlapati received his B.S. and M.S. in Biology fromuniversities in India, and he received his Ph.D. from theUniversity of Illinois at Urbana, as well as conducting post-doctoral work at Yale University.

Lawrence J. Lesko, Ph.D., F.C.P.Lawrence J. Lesko is the Director of theOffice of Clinical Pharmacology (OCP) inthe Center for Drug Evaluation andResearch at the Food and DrugAdministration (FDA) having served inthis capacity since 1995. The main areasof responsibility of OCP are bioavailabili-

ty and bioequivalence of drug delivery systems, systemicpharmacokinetics (PK) and pharmacodynamics (PD), phar-macogenomics and individualization of drug therapy. OCPalso conducts analysis of dose-response and PK-PD data forthe purpose of optimizing dose selection and making doseadjustments in the cases of drug-drug interactions and spe-cial populations (e.g., pediatrics). Members of OCP also uti-lize quantitative methods and drug-disease state-placebomodels to prospectively evaluate options for designing ran-domized clinical trials through simulation. OCP reviewersuse genomic and non-genomic biomarkers to assist in ben-efit/risk assessments and to guide individualization of drugtherapy in both new and previously approved drug labels.Dr. Lesko is Chair of the FDA Pharmacogenomics WorkingGroup and the Clinical Pharmacology Section of theMedical Policy Coordinating Committee in CDER, both ofwhich are responsible for the development of guidances forindustry and enabling of innovative technologies for drugdevelopment. Dr. Lesko has served as the President of theAmerican College of Clinical Pharmacology (ACCP) from2004-2006. He has received the ASCPT Rawls-PalmerProgress in Medicine Award in March 2007, was honoredwith the University of North Carolina (UNC) Institute forPharmacogenomics and Individualized Therapy Award forClinical Service in May 2007, and was awarded theNathaniel T Kwit Memorial Distinguished Service Awardfrom ACCP in September 2007. He has been appointed asan Adjunct Professor in the Colleges of Pharmacy at theUniversity of Florida, at the University of North Carolina,Ohio State University, and at the University of SouthernCalifornia. Dr. Lesko is an elected American Association ofPharmaceutical Scientist (AAPS) Fellow; he is also a Fellowin the ACCP and was elected as a Fellow in the JapaneseSociety for the Study of Xenobiotics (JSSX) in 2009. He isBoard Certified in Clinical Pharmacology by the AmericanBoard of Clinical Pharmacology. He has authored over 165

peer-reviewed manuscripts and is a frequent invited speak-er nationally and internationally. His hobbies includemotorcycles, scuba diving and underwater photography. Heis a Divemaster certified by the Professional Association ofDiving Instructors.

Sharon Levine, M.D.Sharon Levine, Associate ExecutiveDirector for The Permanente MedicalGroup of Northern California since 1991has responsibility for clinical education,management training and leadershipdevelopment for the group’s physicians;government and community relations,

health policy and external affairs; and pharmacy policy anddrug use management.A board certified pediatrician, Dr. Levine has held multi-

ple leadership roles within The Permanente Medical Group,as well as academic appointments at Tufts UniversitySchool of Medicine and Georgetown University School ofMedicine, and spent two years as a Clinical Associate at theNational Institutes of Health, Institute of Child Health andHuman Development. Dr. Levine serves on the Boards of Directors of the

Integrated Healthcare Association, the Public HealthInstitute of California, the California Association ofPhysician Groups (CAPG), The Reagan Udall Foundation, theMedical Board of California and is a member of theCommittee on Evidence-Based Benefit Design of theNational Business Group on Health. In September 2010 shewas appointed to the Board of Governors of the newly cre-ated Patient Centered Outcomes Research Institute.A native of Boston, Dr. Levine received her undergraduate

degree from Radcliffe College at Harvard University, and herMD degree from Tufts University School of Medicine. Dr.Levine is married and lives in Palo Alto, California.

Clay Marsh, M.D.Senior Associate Vice President, HealthSciences Research; Vice Dean of Researchfor the College of Medicine; ExecutiveDirector, Center for Personalized Health;Director, Center for Critical Care andRespiratory Medicine; Professor ofInternal Medicine. He is an NIH-funded

investigator and his laboratory focuses on translationalresearch in the area of macrophage biology and under-standing molecular mechanisms underlying human healthand wellness.

19

Dr Marsh leads the efforts in Personalized Health Care atthe Ohio State University, where he and senior leadershiplead the effort in transforming health care delivery by creat-ing pilot programs in wellness and chronic disease testingdisruptive solutions that will result in lower cost and higherquality/outcomes. OSU is a partner in the Coriell Institute’sPersonalized Medicine Collaborative and has recentlyentered a partnership with the Seattle-based Institute forSystems Biology to form the P4 Medicine Institute.

Christopher-Paul Milne, D.V.M.,M.P.H., J.D.Christopher-Paul Milne joined the TuftsCenter for the Study of DrugDevelopment (Tufts CSDD) in 1998 as aSenior Research Fellow in order toaddress legal and regulatory issues. Hiscurrent research interests include: chal-

lenges to the R&D of new drugs; innovation capacity in thedeveloping world; incentive programs for pediatric studies,orphan products, and neglected diseases; assessing theimpact of regulatory policy; and, tracking progress of newsafety and science initiatives. He is currently a member ofthe Editorial Board of the Food & Drug Law Journal and theExecutive Program Committee for the Drug InformationAssociation 2010 Annual Meeting, as well as an HonoraryFellow at the University of Edinburgh.

Arnold Milstein, M.D., M.P.H.Arnold Milstein is a Professor ofMedicine at Stanford and directs theStanford Clinical Excellence ResearchCenter. The Center is a collaboration ofthe Schools of Medicine, Engineering andBusiness to design and test new healthcare delivery models that both lower per

capita health care spending and improve clinical outcomes. His career and ongoing research is focused on accelera-

tion of clinical service innovations that improve the societalvalue of health care. He serves as the Medical Director of the Pacific Business

Group on Health (PBGH), the largest regional health careimprovement coalition in the U.S. He also guides employer-sponsored clinically-based innovation development forMercer Health and Benefits and chairs the SteeringCommittee that directs the largest U.S. physician pay-for-performance program, operated by the IntegratedHealthcare Association. Previously he co-founded theLeapfrog Group and Consumer-Purchaser Disclosure

Project, and served as a Congressionally-appointedMedPAC Commissioner. Citing his nationally distinguished innovation in health

care cost reduction and quality gains, he was selected forthe highest annual award of the National Business Groupon Health (NBGH) and of the American College of MedicalQuality. Elected to the Institute of Medicine (IOM) of theNational Academy of Sciences, he chaired the planningcommittee of its examination of best methods to lower percapita health care spending and improve clinical outcomes. He was educated at Harvard (BA Economics), Tufts (MD)

and (UC Berkeley MPH Health Services Evaluation andPlanning).

Elizabeth Nabel, M.D.Elizabeth G. Nabel, MD, is the presidentof the Brigham and Women's/FaulknerHospitals, a position she assumed on Jan.4, 2010. Prior to her position at BWH, DrNabel served as the director of theNational Heart, Lung, and Blood Instituteat the National Institutes of Health. In

this capacity, Dr. Nabel oversaw an extensive nationalresearch portfolio with an annual budget of approximately$3.0 billion to prevent, diagnose, and treat heart, lung, andblood diseases. A native of St. Paul, Minnesota, she attend-ed Weill Cornell Medical College and conducted her internalmedicine and cardiovascular training at Brigham andWomen’s Hospital, Harvard Medical School, followed byfaculty positions at the University of Michigan MedicalSchool where she directed the Division of Cardiology andthe Cardiovascular Research Center. As a physician-scientist, Dr. Nabel has made substantial

contributions to our understanding of molecular genetics ofcardiovascular diseases. She has delineated the mechanismsby which cell cycle and growth factor proteins regulate theproliferation of vascular cells in blood vessels, a processimportant for the development of atherosclerosis and othercardiovascular diseases. Her current work has focused onthe rare premature aging disorder, Hutchinson-GilfordProgeria Syndrome, where she has characterized thesmooth muscle cell defect leading to premature heartattack and stroke in children in their early teens. Among her leadership efforts as NHLBI director, Dr. Nabel

launched new scientific programs in genetics and genomics,stem and progenitor cell biology, translational research,global health, and support for young investigators. Her awards include the Willem Einthoven Award; the

Amgen-Scientific Achievement Award; the American Heart

continued

20

Association Distinguished Achievement Awards; the EugeneBraunwald Academic Mentorship Award; the DistinguishedAlumni Award from Weill Cornell Medical College; theLewis Katz Research Prize in Cardiovascular Research andfour honorary doctorates. Dr. Nabel received the 2006Leadership in Personalized Medicine Award from thePersonalized Medicine Coalition. She is a member of theAmerican Academy of the Arts and Sciences, the Institute ofMedicine (Council) of the National Academy of Sciences,the Association of American Physicians (Council), and a fel-low of the American Association for the Advancement ofScience. Dr. Nabel has served on the Board of ReviewingEditors for Science and currently is on the Editorial Board ofthe New England Journal of Medicine and ScienceTranslational Medicine. She is a partner on 17 patents andthe author of more than 250 scientific publications. Dr. Nabel’s pledge is to strengthen the mission of the

Brigham and Women’s/Faulkner Hospitals and their connec-tions to the people and the communities that they serve,whether they live across street or around the world.

David Parker, Ph.D.David Parker has spent the past 25 yearsin the healthcare industry, including 14years of strategy consulting experiencecentered on the intersection of reim-bursement, health economics, clinical sci-ence, and marketing strategy. He current-ly leads the Washington office of Boston

Healthcare Associates and provides strategic advisory serv-ices to the firm’s biopharma, device, and diagnostics clients.His consulting encompasses all aspects of reimbursementand market strategy development with a particular focus onmedical devices, molecular diagnostics, and personalizedmedicine. Preceding his appointment at Boston Healthcare,he was a senior consulting executive at Covance MarketAccess Services, where as a Vice President he led theEconomic Strategies and Devices/Diagnostics practices. Hiswork has resulted in numerous successful product launches,expanded market access, and favorable coverage and pay-ment decisions by public and private payers alike. Prior to Covance, Dr. Parker was president of a biomedical

consulting firm. His consulting career was preceded byeleven years of increasingly-responsible product and mar-keting management, strategic planning, and business devel-opment roles at several biotechnology companies rangingfrom development-stage to Fortune 500. Early in his career,he conducted research in cell biology at NorthwesternUniversity Medical School.

Dr. Parker received a Ph.D. in Cell and DevelopmentalBiology from the Massachusetts Institute of Technology, andan A.B. with high honors in Biochemistry from PrincetonUniversity.

Ryan PhelanRyan Phelan is the Founder & Presidentof DNA Direct, a San Francisco-basedcompany launched in 2005 that deliversguidance and decision support forgenomic medicine to patients, providersand health plans. DNA Direct is pioneer-ing the translation of genomic medicine

into patient care by providing genetic expertise and Web-based decision support to the healthcare industry. InFebruary 2010, DNA Direct became a wholly owned sub-sidiary of Medco Health Solutions, the country's largestpharmacy benefit manager and one of the most innovativecompanies in healthcare.Phelan has been a strong consumer health advocate for

the past 25 years, having started the first medical library forconsumers in 1978. As Founding Director of Planetree, anonprofit consumer health care organization, she helpedcreate a national model for humanizing hospitals. Today thePlanetree Alliance is a group of over 85 innovative hospitalsand health care institutions with shared values, goals andexperiences dedicated to implementing Planetree programs.In 1995 she founded Direct Medical Knowledge (DMK).

DMK developed proprietary software that enabled users todrill down through the most current medical literature andretrieve personalized health and medical information. In1999 Direct Medical Knowledge was acquired by WebMD,and its content became the backbone of WebMD's con-sumer health site.

Sara RadcliffeSara Radcliffe is the Executive VicePresident for Health at the BiotechnologyIndustry Organization (BIO). Previouslyshe served as BIO's Vice President forScience and Regulatory Affairs. Ms.Radcliffe has responsibility for identify-ing, developing and implementing strate-

gic BIO approaches to improving the ability of BIO's humanhealthcare focused companies to research and developproducts, and to bring these products to market. Beforejoining BIO, Ms. Radcliffe was Senior Director, Biologics &Biotechnology, and Assistant Vice-President, Preclinical DrugSafety Evaluation, at the Pharmaceutical Research and

Conference Speakers continued

21

Manufacturers of America (PhRMA). Among her responsibil-ities at PhRMA were to staff the PhRMA Vaccines CEOsCommittee and the PhRMA Emergency Preparedness TaskForce. She also worked for the Alliance and TechnologyGroup at SmithKline Beecham Pharmaceuticals as aResearch and Development Policy Analyst, where her workfocused on evaluation and communication of the promise,ethics, and impact of rapidly-developing technologies inDNA Research, including Pharmacogenetics. In addition sheworked for the Core Services Committee of the NewZealand Ministry of Health. Ms. Radcliffe holds a Master'sof Public Health and a Masters in Philosophy from theJohns Hopkins University.

Emad Rizk, M.D.Emad Rizk is president of McKessonHealth Solutions, a division of McKessonCorporation, that delivers intelligenthealthcare solutions that enable payors,providers, and patients to come togetherto transform the business and process ofhealthcare.

A world renowned healthcare industry expert, Dr. Rizkbrings over 25 years of experience working with payors,physicians, hospital systems and pharmaceutical organiza-tions. He provides the healthcare industry, both the com-mercial and government sectors, with transformationalstrategies and operational execution expertise throughhealthcare information technology.In his previous position as the global director of Deloitte,

Rizk led medical cost and quality management practiceacross all industries. He also spearheaded the largestredesign of care management and delivery models amonghealth plans and providers nationwide.Rizk is sought after for his knowledge of the healthcare

industry. He has served on many healthcare boards, includ-ing the National Clinical Advisory Board and NationalQuality Review, and currently serves on the boards ofDMAA: Care Continuum Alliance, National Association forHispanic Health, University of Miami, University of NorthTexas, and Managed Care Magazine.Rizk is a senior scholar Professor at Jefferson Medical

College in Philadelphia and has an extensive portfolio ofpublished journal articles and books, including his contribu-tion to The Wisdom of Top Health Care CEOs, a collection ofinterviews published in 2003. His new book The New Era ofHealthcare: Practical Strategies for Providers and Payerscenters on methods to forge a partnership betweenproviders and payors focused on clinical, administrative,

and economic alignment to bring about more efficient,cost effective care.Rizk was selected as one of the Modern Physician 50

Most Powerful Physician Executives for 2010. Ranked atnumber eight on the list, this is Rizk’s second year in thetop ten and third consecutive year recognized by this pro-gram. Dr. Rizk has also been named among the Top 100Most Powerful People in Healthcare by Modern Healthcarefor the last two years, and one of the nation’s Top 25Leaders in Disease Management by Managed HealthcareExecutive in 2008.

Sue Siegel Sue Siegel is a Partner at Mohr, DavidowVentures, a top tier Silicon Valley venturefirm. She leads investments in compa-nies focused on personalized medicine,enabling platform technologies for bio-medical research, and innovative health-care companies with disruptive business

models. Prior to joining MDV, Sue was President andDirector of Affymetrix, Inc., (NASDAQ: AFFX) a companythat pioneered GeneChip® technology, which helped accel-erate the advent of personalized medicine in modern medi-cine. Sue serves on the board of directors of PacificBiosciences, Navigenics, Crescendo Biosciences, Corventis,RainDance Technologies and On-Q-ity. As a member of the Presidents’ Circle of the National

Academies, Sue serves as an advisor to the Institute ofMedicine. She is board member emeritus of The SiliconValley Tech Museum, serves on The Gladstone InstitutesAdvisory Council and the Stanford ITI Council, is a YPOmember, and a Henry Crown Fellow of the Aspen Institute.As part of the Crown Fellowship, Sue and her husband co-founded with Stanford Hospital, Checking-In™, an organi-zation dedicated to serving our aging population.

Risa Stack, Ph.D.Risa Stack has 15 years of experience investing in personal-ized medicine, therapeutics, and platform technologies. Herinvestment career spans incubations to public companies.Most recently she has focused starting companies, oftentaking operational roles. Since joining Kleiner Perkins Caufield & Byers in 2003,

Risa has worked to build and support KPCB's personalizedmedicine portfolio. She has been the founding CEO and aboard member of several personalized medicine companiesincluding Nodality and CardioDx. In addition to her workdirectly with portfolio, Risa is involved in developing public

22

policy in molecular diagnostics and personalized medicine.Risa is involved in the development of therapeutics com-

panies including Trius and Corthera. She was most recentlya board member of Corthera which was sold to Novartis inDecember 2009. She is also a board observer at Epizymeand Pacific Biosciences.Prior to joining KPCB, Risa was a Principal at J.P. Morgan

Partners in the life science practice for six years. While atJ.P. Morgan Partners she sponsored a series of investmentsincluding Acurian, Connetics (acquired by SteifelLaboratories), Diatide (acquired by Berlex), Ilex Oncology(acquired by Genzyme), Illumina, and TrianglePharmaceuticals (acquired by Gilead). Risa was alsoinvolved in JP Morgan Partners' international investingefforts, which included European life sciences companiesand managing a portfolio of Israeli early stage life scienceand IT companies. Before joining the venture capital industry, Risa worked

as a Derivative Specialist on the Chicago Board of Tradewhere she traded futures and options on government secu-rities. Risa received her B.S. in Genetics and Development with

distinction from the University of Illinois and her Ph.D. inImmunology from the University of Chicago. She was also amember of the second class of Kauffman Fellows.Risa is a member of the advisory board of the National

Summit on Personalized Healthcare and GE'sHealthymagination effort. She was named as one of the100 Most Influential Women in Business by the SanFrancisco Business Times in 2004.

Mark P. StevensonMark P. Stevenson serves as Presidentand Chief Operating Officer of LifeTechnologies. From December 2007 to November

2008, Mr. Stevenson served as Presidentand Chief Operating Officer of AppliedBiosystems, which merged with

Invitrogen Corporation in November 2008 to form LifeTechnologies. He joined Applied Biosystems in Europe in1998, and held roles of increasing responsibility in Europeand Japan. He moved to the U.S. in 2004 to establishApplied Biosystems’ Applied Markets Division and in 2006was named President of the Molecular and Cellular BiologyDivision. Mr. Stevenson has more than 20 years of sales, market-

ing, and international executive management experience

and received his bachelor's degree in chemistry from theUniversity of Reading, UK, and an M.B.A. from HenleyManagement School, UK. He serves on the board oftrustees of the Keck Graduate Institute.

Guilherme Suarez-Kurtz, M.D., Ph.D.Guilherme Suarez-Kurtz is the Head ofPharmacology at the Brazilian NationalCancer Institute and the Coordinator ofthe Brazilian NationalPharmacogenetics Network (Refargen).A pioneer of pharmacogenetic studies inthe Brazilian population, his research

explores the impact of genetic admixture on the conceptualdevelopment and the praxis of pharmacogenetics/-genomics (PGx). He is a Member of the Brazilian Academyof Sciences, Senior Investigator of the Brazilian NationalResearch Council and Professor of Clinical and BasicPharmacology at Universidade do Brasil, in Rio de Janeiro,from which he received his M.D. and Ph.D. degrees. Prof.Suarez-Kurtz did postgraduate work at Faculté de Médecinede Paris, Columbia University New York and UniversityCollege London. In 2007 he was the editor ofPharmacogenomics in Admixed Populations, published byLandes Bioscience, a collection of essays on various aspectsof PGx and a database for PGx data from peoples of fourcontinents. Presently he serves as a member of IUPHAR´sCommittee of Clinical Pharmacology and sub-Committee ofPharmacogenetics, and is Associate Editor of CurrentPharmacogenomics and Personalized Medicine and ofFrontiers in Pharmacogenetics.

Charles Swanton, Ph.D.Charles completed the MDPhD pro-gramme at University College London in1999 having gained his PhD from thelaboratory of Nic Jones at the ImperialCancer Research Fund Laboratoriesestablishing the subversion of cell cyclecontrol by the Kaposi’s Sarcoma

Herpesvirus encoded K-Cyclin (Swanton et al. Nature 1997)and was awarded the national Pontecorvo Imperial CancerResearch Fund PhD thesis award (Mann et al., 1999;Swanton et al., 1999; Swanton et al., 1997).Charles continued his interest in cell cycle disruption in

cancer and its therapeutic applications (Swanton, LancetOncology 2004) and was made a Member of the RoyalCollege of Physicians in 2003 and subsequently undertook

Conference Speakers continued

23

his medical oncology training at the Royal MarsdenHospital. He was awarded a Cancer Research UK (CR-UK)clinician scientist fellowship in 2004 which allowed him toconduct his post-doctoral research training at the CR-UKLondon Research Institute with Prof Julian Downward,establishing multi-drug sensitivity mechanisms throughRNA interference screening approaches, associated withpaclitaxel and other common chemotherapy agents used inoncological practice (Swanton et al., 2007a; Swanton et al.,2007b). These screening datasets resulted in the observa-tion that molecules that mediate chromosomal stabilityappeared to be significantly associated with those mediat-ing taxane sensitivity and led to the first phase II clinicaltrial in colorectal cancer to attempt to define prospectivelywhether tumour chromosomal instability status altersresponse to a taxane-like drug.In 2008, Charles was awarded an MRC and a CR-UK sen-

ior clinical research fellowship and appointed MRC/CR-UKGroup leader of the Translational Cancer TherapeuticsLaboratory at the CRUK London Research Institute andFellow of the Society of Biologists (FSB). His laboratoryfocus is aimed at identifying colorectal and breast cancercell survival regulators associated with specific patterns ofgenomic instability using functional genomic techniques inorder to develop therapeutic approaches to delay the acqui-sition of multi-drug resistance (Swanton and Caldas, 2009;Swanton and Downward, 2008; Swanton et al., 2008;Swanton et al., 2006). During this period Charles’ research has begun to estab-

lish the clinical relevance of RNA interference (RNAi)approaches to the elucidation of drug sensitive patientcohorts; Tumours harbouring a Chromosomal Instability(CIN) phenotype are relatively more resistant to paclitaxeland sensitive to carboplatin in the OV01 ovarian cancerclinical trial cohort, potentially explaining the combinatorialefficacy of these two cytotoxics in vivo (Swanton et al.,2009). Charles has also recently confirmed the ability ofRNAi screening methods to generate clinically applicablepredictive biomarkers of drug response in breast cancer(Juul et al., 2010). Current translational research is develop-ing these observations, focussed on the rapid identificationof predictive biomarkers of drug response in cancer usingRNAi screening approaches combined with the parallelgenomics analysis of tumour tissue derived from “windowof opportunity” neo-adjuvant monotherapy clinical trials. Charles conducts his clinical research activities at the

Royal Marsden Hospital having been appointed a medicaloncology consultant physician in 2008. He combines his

laboratory work with clinical duties by aiming to directnovel therapeutics to patients with specific cancer molecu-lar subtypes within clinical trials in the Breast Cancer andDrug Development Units.

Sheila D. Walcoff Sheila D. Walcoff is a partner in the lawfirm of McDermott Will & Emery LLP inWashington DC where she focuses herpractice on genomics and personalizedmedicine, FDA regulatory advice, medicalproduct reimbursement policies, CLIArequirements, and legislative strategy

and advocacy on medical products and related scienceissues. Her clients include innovative diagnostic companies,clinical laboratories, coalitions and associations, a diagnos-tic standards entity, pharmaceutical and biotechnologycompanies. Ms. Walcoff served as health and science policycounselor to HHS Secretary Leavitt, Associate Commissionerfor External Affairs at the Food and Drug Administration(FDA), and the health policy team leader/senior health poli-cy advisor to a 2008 presidential campaign. She alsoserved as the majority counsel to the U.S. House ofRepresentatives Armed Services Committee. Her ongoingpro bono work includes legislative and policy counsel to anational eating disorder association. Ms. Walcoff servedas a member of the HHS Secretary’s

Advisory Committee on Genetics, Health and Society(SACGHS) from 2008- 2010,and is a member of theMassachusetts Institute of Technology (MIT) Center forBiomedical Innovation (CBI) Strategy and Policy Councilandthe Board of the Friends of the National Zoo (FONZ) inWashington DC. She is a frequent speaker on genomics,personalized medicine and related medical product and lab-oratory regulation and reimbursement issues. She recentlyco-authored an article on evidentiary standards for compar-ative effectiveness research and has a authored book chap-ter on recent developments in FDA law and policy. Outsideof her law practice, Ms. Walcoff is a life-longentrepreneurwho co-founded several veterinary hospitals.

24

Scott Weiss, M.D., M.S.Dr. Weiss is currently Director of thePartners HealthCare Center forPersonalized Genetic Medicine (PCPGM)and Associate Director, ChanningLaboratory, and Professor of Medicine atHarvard Medical School. In this lattercapacity, he leads a 28 investigator, 120

person research group examining the environmental andgenetic origins of asthma and COPD. He has authored or coauthored over 500 publications

and four books in the area of asthma and COPD risk fac-tors, natural history, and genetics. His initial work con-cerned the role of airways responsiveness and environmen-tal tobacco smoke exposure in asthma and COPD, the effectof allergen exposure and airways responsiveness on mark-ers of inflammation and the combined effect of these fac-tors on the development of COPD. In 1996, he developed astrong interest in the genetics of asthma and his work overthe past 14 years has focused on this, and novel environ-mental exposures such as vitamin D and the bowel flora.His laboratory is the only laboratory in the world that hasactive NIH research in the areas of asthma genetics, asthmapharmacogenetics, and COPD genetics. He is the principalinvestigator or co-investigator on a total of six separateNHLBI-funded grant proposals in the area of the genetics ofasthma and Asthma Pharmacogenetics, including a MERITaward.

M. Kathleen Behrens Wilsey, Ph.D.Kathleen Behrens Wilsey served as aMember of the President's Council ofAdvisors on Science and Technology(PCAST), from 2001 to 2009, working onmultiple national policy matters. SheChaired PCAST'sSubcommittee onPersonalized Medicine and led a two

year study that culminated in the September 15, 2008report, Priorities for Personalized Medicine. Kathy was adirector of the Board on SCience, Technology and EconomicPolicy (STEP) for the National Research Council from 1997-2005, at which time she participated as a member of theInstitute of Medicine Committee on New Approaches toEarly Detection and Diagnosis of Breast Cancer. Kathy wasa director of the National Venture Capital Association from1993 to 2000, also serving as President, Chairman and PastChairman from October of1999 through April of 2000. Dr.Behrens Wilsey currently serves as a member of the Boardof Directors of Amylin Pharmaceuticals, Inc., AVI Biopharma,

Inc and KEW Group LLC. Kathy holds a Ph.D. inMicrobiology from the University of California, Davis.Kathy established a career in the financial services indus-

try, working with Robertson Stephens & Co. until 1996,where she became a general partner and managing direc-tor. Dr. Behrens Wilsey continued in her capacity as aGeneral Partner for selected venture funds for RSInvestments, after management led a buy-out of that firmfrom Bank of America. Her professional career includestenures as a public-market lifesciences securities analyst, aswell as venture capitalist focusing on healthcare and tech-nology investments. She was instrumental in the foundingof several life-sciences companies including Protein DesignLabs, Inc. and CORTherapeutics, Inc. and participated infinancing a broad range of health care services and prod-ucts companies. More recently, Kathy served as a director ofAbgenix, Inc. in a role that spanned that firm's early roundsof private financings through the company's sale in 2006 toAmgen, Inc. Dr. Behrens Wilsey has worked for the last twoyears with KEW Group LLC in developing a fully integratedpersonalized medicine oncology management company .

Conference Speakers continued

25

The Partners HealthCare Center forPersonalized Genetic Medicine(PCPGM) was launched in 2001 as theHarvard Medical School-PartnersHealthCare Center for Genetics andGenomics. Its purposes from its found-ing have been to promote genetics andgenomics in research and clinical medi-cine and to help realize the promise ofpersonalized medicine by acceleratingthe integration of genetic knowledgeinto clinical care throughout thePartners HealthCare System (PHS) andin healthcare nationally and globally.PCPGM is accomplishing its mission bysupporting and facilitating:• pursuing important discoveries thatwill enable advancing the knowledgeof how genetics affects human healthand disease• offering genetic-based diagnostictesting and developing new teststhrough a CLIA- and state-approvedLaboratory for Molecular Medicine• developing an IT infrastructure tointegrate genetic and genomic datainto clinical decision support systems• educating practicing clinicians, inves-tigators, health care professionals• developing a program inPersonalized Predictive MedicinePersonalized medicine is the ability

to determine an individual’s uniquemolecular characteristics and to usethose genetic distinctions to diagnosemore finely an individual’s disease,

select treatments that increase thechances of a successful outcome andreduce possible adverse reactions.Personalized medicine also is the abili-ty to predict an individual’s susceptibil-ity to diseases and thus to try to shapesteps that may help avoid or reducethe extent to which an individual willexperience a disease.For personalized medicine to be a

fully functioning reality at the clinicallevel, certain elements are essential: anelectronic medical record, personalizedgenomic data available for clinical use,physician access to electronic decisionsupport tools, a personalized healthplan, personalized treatments, and per-sonal clinical information available forresearch use. Partners HealthCare hasmade a firm commitment to the princi-ples of personalized medicine and tothe importance of genetics andgenomics in delivering the best care ofpatients. PHS also has committed toensuring that the features above are orwill be available.The essential feature of the revolu-

tion in genetics and genomics hasbeen an explosion in the amount ofdata available for use in translationalresearch. This massive data profusionhas enhanced our ability to predictclinical phenotypes and to predict clini-cal outcomes on the basis of genomescale data. However, to be able to dothis sort of prediction investigators

need several tools. First, they need arobust bioinformatics infrastructurewith secure pipelines and robust algo-rithms for data cleaning and manipula-tion. Second, they need very strongbioinformatics platforms for dataanalysis and data management. Third,they need access to large numbers ofvery well phenotyped patients. Fourth,they need access to the genomic plat-forms to create genomic scale data onthese patients for prediction of clinicaloutcomes. Finally, they need novel sta-tistical and bioinformatics methods toanalyze these data for predictive medi-cine. PCPGM makes all of theseresources available to Partners investi-gators through a highly developedinfrastructure consisting of bioinfor-matics and genetic statistics; biosam-ple repository; core sequencing, geno-typing and GeneChip® and microarraylaboratories; and information technolo-gy services.

For more information about PCPGM,please visit http://pcpgm.partners.org.

Partners HealthCare Center for Personalized Genetic Medicine

Harvard Business School’s mission is to train business lead-ers in all industries. Healthcare, a $2 trillion industry, hasbecome one of the school’s key priorities. The HealthcareInitiative at HBS was launched in 2005 to bring together theextensive research, thought leadership, and interest in thebusiness and management of healthcare that exists at HBS. Healthcare research at HBS focuses on entrepreneurship,

innovation and disruption. Faculty and students seek tounderstand and identify new products, services and deliverymethods that will help to reshape the industry. HBS believesthis focus on “creative destruction” will result in business

models that offer the hope of improved outcomes, reducedcosts, streamlined systems, and enhanced services. Personalized medicine presents tremendous opportunities

in healthcare and has garnered much attention at HBS. Withits expertise in technology, commercialization, and businessmodel development, HBS can play a critical role in the wide-spread adoption of personalized medicine applications.

For more information about the HBS HealthcareInitiative, please visit www.hbs.edu/healthcare.

Harvard Business School

26

Raju Kucherlapati, Ph.D., ChairPaul C. Cabot Professor of Genetics,Professor of MedicineHarvard Medical School

Edward Abrahams, Ph.D.PresidentPersonalized Medicine Coalition

Mara G. AspinallPresident and CEOOn-Q-ity

Brook ByersPartnerKleiner Perkins Caufield & Byers

Nadine Cohen, Ph.D.Head of Pharmacogenomics and Senior Research FellowJohnson & Johnson PharmaceuticalResearch and Development East Coast and Europe

Neil de CrescenzoSenior Vice President and General ManagerOracle Health Sciences Global Business Unit

Frank Douglas, Ph.D., M.D.President and CEOAusten BioInnovation InstituteFounderPureTech Ventures

Gregory Downing, Ph.D.Senior Advisor and Director, Personalized Health Care Initiative The U.S. Department of Health andHuman Services

Robert S. Epstein, M.D., M.S.Chief Medical Officer and President,Medco Research InstituteMedco Health Solutions, Inc.

Kathy GiustiFounder and CEOMultiple Myeloma Research Foundation(MMRF)

John P. Glaser, Ph.D.CEO, Health Services DivisionSiemens Medical Solutions

Richard G. Hamermesh, D.B.A.MBA Class of 1961 Professor ofManagement PracticeFaculty Chair, HBS Healthcare InitiativeHarvard Business School

Katherine Johansen, Ph.D.Senior Scientist, Genetics and Molecular MedicineAmerican Medical Association

Marcia A. KeanCEOFeinstein Kean Healthcare

David P. KingPresident and CEOLaboratory Corporation of America

Gerald J. McDougallPartnerPricewaterhouseCoopers

Lori M. ReillyVice President for Policy and ResearchPhRMA

Hakan Sakul, Ph.D.Senior Director, Translational Oncology GroupPfizer – Oncology Business Unit

Sue SiegelPartnerMohr, Davidow VenturesScott Weiss, M.D., M.S.Professor of Medicine, Harvard Medical SchoolDirector, Partners HealthCare Centerfor Personalized Genetic Medicine

Robert WellsHead, Biotechnology Unit, Science and Technology Policy DivisionDirectorate for Science, Technology and IndustryOrganisation for Economic Co-operation and Development (OECD)

M. Kathleen Behrens Wilsey, Ph.D.FounderKEW Group, LLC

PCPGM CONTACTS

Alfred A. Blum, Jr.Chief Development OfficerPartners HealthCare Center forPersonalized Genetic Medicine (PCPGM)

Janice LarsonDevelopment AssociatePartners HealthCare Center forPersonalized Genetic Medicine (PCPGM)

Amy McGlinnProgram CoordinatorPartners HealthCare Center forPersonalized Genetic Medicine (PCPGM)

Rebecca RehmProgram AssociatePartners HealthCare Center forPersonalized Genetic Medicine (PCPGM)

Conference Organizing Committee

28

Design: Vergara Design Photography: Justin Knight Photography

Personalized Medicine: Impacting Healthcare

Alfred A. Blum, Jr.Chief Development Officeraablum@partners.org

Meini Sumbada ShinAdministrative Director

msumbadashin@partners.org

Rebecca RehmProgram Associaterrehm@partners.org

Amy McGlinnProgram Coordinatoramcglin@partners.org

Conference staffPartners HealthCare Center for Personalized Genetic Medicine

Scott Weiss, M.D., M.S.Scientific Director, Partners HealthCare Center for Personalized Genetic MedicineProfessor of Medicine, Harvard Medical School, Brigham and Women’s Hospital

SAVE THE DATE7th Annual Personalized Medicine Conference

November 9-10, 2011

www.personalizedmedicineconference.org

Janice LarsonDevelopment Associatejalarson@partners.org